B
쎌바이오텍
049960KOSDAQ60.0 / 100
Reference Date: 2026-10-23
Financial Score27.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 2.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Sebaitech operates in three main areas: probiotics, microbiome, and anti-cancer drug development. It maintains the top position in South Korea's probiotic exports and is developing functional foods for atopic dermatitis and menopausal symptoms through its microbiome business. The company also aims to create probiotic-based therapies for ulcerative colitis and colorectal cancer.
Number of Employees
123people
Average Salary
45.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
10.31Industry Average 15.006.5Point
Lower than industry avg (good)
PBR
1.09Industry Average 1.204.0Point
In line with industry avg
ROE
7.92Industry Average 8.002.5Point
Below industry avg
Debt Ratio
0.06Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼0.4% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲113.0% (2-year basis)
ROE Trend
3.0 / 4
Avg ROE 8.8% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (56%)
Current 15,250Won52-week high 18,11052-week low 11,500
1-month return2.0Point
1m -2.49% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0